Cancer Center

Henri and Belinda Termeer Center for Targeted Therapies

Setting the Standard for Excellence in Personalized Cancer Care


The Henri and Belinda Termeer Center for Targeted Therapies offers new hope to patients and their families at the Massachusetts General Hospital Cancer Center and beyond, as the center defines the future of cancer therapy.

Led by Keith T. Flaherty, MD, a renowned expert in personalized cancer medicine and melanoma specialist, the Termeer Center offers a comprehensive translational research program to speed the discovery and delivery of new targeted therapies to patients with early and advanced stage cancers.

The Termeer Center brings together cutting-edge research resources and provides a foundation for collaborations among physicians and investigators from a broad spectrum of biomedical disciplines, resulting in a rapidly expanding arsenal of weapons against cancer. Leading specialists from the Cancer Center’s 24 disease centers participate in the Termeer Center by enrolling their patients in its fast-growing portfolio of Phase I, Phase II and Phase III clinical trials.

The cycle of discovery is swift and efficient, with newly identified genetic abnormalities revealing new information about cancer pathways and creating novel investigative possibilities, not only for Mass General researchers but for scientific collaborators around the world. The Termeer Center's goal is to cut the average time for drug development from ten years to five and, with more clinical trials, improve access to therapy for patients. With hundreds of new anti-cancer therapies now in the development pipeline and countless patients waiting for targeted drugs that match their individual tumors, the Termeer Center's work is vital and timely.

What is Personalized Cancer Medicine?

The Mass General Cancer Center is a world leader in personalized cancer medicine, the concept of matching molecularly-targeted treatments to specific genetic abnormalities that enable cancer cells in a patient's tumor to thrive. The Cancer Center's proven track record of discovery includes significant breakthroughs in lung cancer, melanoma and breast cancer, among others.

How is the Termeer Center Different?

In many ways, the Termeer Center represents a paradigm shift from traditional clinical cancer research. For example, in traditional clinical trials, experimental therapies are tested first in patients who have not responded to standard treatments; with genotype-based targeted therapies, clinical trials can begin at a much earlier stage of the disease process, when the chances of observing benefits for the patient are far greater. Additionally, since various forms of cancer have been found to share common tumor mutations, researchers are learning to apply targeted drugs across multiple tumor types.

Unique Resources and Strengths

  • The Translational Research Laboratory enables SNaPshot genotyping for more than 130 gene mutations commonly found in patients ' tumors. Mass General was the first institution to provide this capability in a clinical setting, and investigators are now working on next generation sequencing, which will have the capacity to detect and analyze thousands of additional mutations.
  • Investigators in the Center for Molecular Therapeutics screen 1,100 human cancer cell lines derived from tumors of virtually every tissue type, including breast, brain, colon, lung, pancreas, kidney, stomach, skin and blood, to identify which genetically-defined subgroups within cancers are sensitive to new molecularly-targeted therapies. The results from this high-throughput screening process inform the selection of patients for subsequent clinical trials investigating these drugs.
  • Strong partnerships with pharmaceutical and biotechnology companies – resulting from a long history of positive collaborations with industry, as well as Mass General leadership of national and international cancer forums – provide access to developmental drugs and generate resources to fund early phase clinical trials.
  • The Mass General Cancer Center treats 17,000 patients each year, including 9,000 new patients. High patient volume is vital to a successful clinical trials program. Additionally, the Cancer Center has long-term relationships with other leading institutions around the world, as well as with community-based cancer centers, enabling collaborative, multi-site, Mass General-led trials.

Advancing Care through Research and Clinical Trials

The Center for Targeted Therapeutics conducts extensive basic and translational research to accelerate the delivery of new, cutting-edge therapies into the clinical setting. Our current research includes:

  • Next generation EGF receptor, HER2, HER3, ALK, c-Met, PI3 kinase, mTOR, FGFR, ERK and BRAF targeted therapies
  • Cyclin-dependent kinase and PARP inhibitors
  • Drugs blocking FGF, Tie-2 and other angiogenesis mediators
  • Cutting-edge imaging methods for determining early response to therapy

Learn more about targeted clinical trials at

Termeer Symposium

The bi-annual Termeer Symposium, presented by the Henri and Belinda Termeer Center for Targeted Therapies, features discussions from leading experts on cutting-edge topics in personalized cancer medicine. Learn more here.


  • Listen to John Murphy's story and learn about advances in targeted cancer therapies.

    John Murphy

    John Murphy has an amazing story to tell. Listen to his story and learn about advances in targeted cancer therapies that are bringing new hope to patients. With the opening of the Henri and Belinda Termeer Center for Targeted Therapies, the Mass General Cancer Center is expanding its phase one clinical trials program to help more patients like him.

  • Dr Keith Flaherty

    Dr. Keith Flaherty

    Dr. Keith Flaherty is the director of the Henri and Belinda Termeer Center for Targeted Therapies. Dr. Flaherty and his exceptional team of clinicians and scientists are spearheading research into promising new treatment options for patients through phase I clinical investigation.

  • Termeer Opening Symposium

    Termeer Center Opening Symposium

    On Oct. 2, 2012, Mass General Cancer Center Director Dr. Daniel Haber hosted an educational symposium to introduce the Termeer Center. Dr. Robert Weinberg of MIT, Dr. José Baselga of Memorial Sloan-Kettering, and Mass General Cancer Center’s own Drs. Keith Flaherty and Jeff Engelman presented to an audience of 125 in the Ether Dome.

  • Termeer Opening Reception

    Termeer Center Opening Reception

    Following the Oct. 2 symposium, a celebratory reception was held in the Termeer Center on Yawkey 7. Hear inspiring remarks by MGH President Dr. Peter Slavin, Mass General Cancer Center Director Dr. Daniel Haber, Termeer Center Director Dr. Keith Flaherty, patient John Murphy and donor Henri Termeer. The reception concluded with a ribbon-cutting.


Contact Us

Cancer Center

  • Phone: 617-726-5130

Back to Top